Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications and thromboembolic events:a Dutch multicenter matched-cohort clinical study by Jonker, Pascal et al.
 
 
 University of Groningen
Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications and
thromboembolic events
Jonker, Pascal; Plas, van der, Willemijn; Steinkamp, Pieter; Poelstra, Ralph ; Emous,






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Version created as part of publication process; publisher's layout; not normally made publicly available
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Jonker, P., Plas, van der, W., Steinkamp, P., Poelstra, R., Emous, M., van der Meij , W., Thunnissen, F.,
Bierman, W. F. W., Struys, M., de Reuver, P. R., de Vries, J-P. P. M., & Kruijff, S. (2020). Perioperative
SARS-CoV-2 infections increase mortality, pulmonary complications and thromboembolic events: a Dutch
multicenter matched-cohort clinical study. Surgery. https://doi.org/10.1016/j.surg.2020.09.022
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Journal Pre-proof
Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications
and thromboembolic events: a Dutch multicenter matched-cohort clinical study
Pascal KC. Jonker, MD, Willemijn Y. van der Plas, BSc, Pieter J. Steinkamp, MD,
Ralph Poelstra, MD, Marloes Emous, MD/PhD, Wout van der Meij, MD, Floris
Thunnissen, BSc, Wouter FW. Bierman, MD/PhD, Michel MRF. Struys, MD/PhD,





To appear in: Surgery
Received Date: 31 August 2020
Accepted Date: 4 September 2020
Please cite this article as: Jonker PK, van der Plas WY, Steinkamp PJ, Poelstra R, Emous M, van der
Meij W, Thunnissen F, Bierman WF, Struys MM, de Reuver PR, de Vries JPP, Kruijff S, Perioperative
SARS-CoV-2 infections increase mortality, pulmonary complications and thromboembolic events:
a Dutch multicenter matched-cohort clinical study, Surgery (2020), doi: https://doi.org/10.1016/
j.surg.2020.09.022.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 The Author(s). Published by Elsevier Inc.
 
1
Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications and 1 
thromboembolic events: a Dutch multicenter matched-cohort clinical study 2 
 3 
Authors: 4 
Pascal KC Jonker, MD*1, Willemijn Y van der Plas, BSc*1, Pieter J Steinkamp, MD*1, Ralph Poelstra, MD2, 5 
Marloes Emous, MD/PhD2, Wout van der Meij, MD3, Floris Thunnissen, BSc4, Wouter FW Bierman, MD/PhD5, 6 
Michel MRF Struys, MD/PhD6,7, Philip R de Reuver, MD/PhD4, Jean-Paul PM de Vries, MD/PhD1, Schelto 7 
Kruijff, MD/PhD1 8 
* contributed equally  9 
This article was submitted on behalf of the Dutch Surgical COVID-19 Research Collaborative (please refe  to 10 
Supplemental File 1 for the list of collaborators and contact details) 11 
 12 
Affiliations 13 
1. Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the 14 
Netherlands 15 
2. Department of Surgery, Medical Center Leeuwarden, Leuwarden, the Netherlands 16 
3. Department of Surgery, Hospital Bernhoven, Uden, the Netherlands 17 
4. Department of Surgery, Radboud University, Radboud University Medical Center, Nijmegen, the 18 
Netherlands 19 
5. Department of Internal Medicine and Infectious Diseas s, University of Groningen, University Medical 20 
Center Groningen, Groningen, the Netherlands 21 
6. Department of Anesthesiology, University of Groninge , University Medical Center Groningen, 22 
Groningen, the Netherlands 23 
7. Department of Basic and Applied Medical Sciences, Ghent University, Gent, Belgium 24 
 25 
Running head: Surgical SARS-CoV-2 infection outcomes 26 
Corresponding author: Schelto Kruijff, MD, PhD, Department of Surgery, University Medical Center 27 
Groningen, PO Box 30.001, 9700 RB Groningen the Netherlands. E-mail: s.kruijff@umcg.nl phone: +31 6 527 28 
24728, Fax: +31 50 361 4873 29 










Abstract  31 
 32 
Background 33 
A direct comparison of SARS-CoV-2 positive patients with a SARS-CoV-2 negative control group undergoin 34 
an operative intervention during the current pandemic is lacking, and a reliable estimate of the assumed 35 
difference in morbidity and mortality between both patient categories remains unknown. 36 
 37 
Methods  38 
We included all consecutive patients with a confirmed pre- or postoperative SARS-CoV-2 positive status 39 
(operated in 27 hospitals) and negative controls (operated in 4 hospitals) undergoing emergency or elective 40 
operations. A propensity score-matched comparison of clinical outcomes was performed between SARS-CoV-2 41 
positive and negative tested patients (control group). Primary outcome was overall 30-day mortality rate between 42 
both groups. Main secondary outcomes were overall, pulmonary, and thromboembolic complications.  43 
 44 
Results 45 
In total, 161 SARS-CoV-2 positive and 342 control SARS-CoV-2 negative patients were included in this study. 46 
The 30-day overall postoperative mortality rate was greater in the SARS-CoV-2 positive cohort compared to the 47 
negative control group (16% vs. 4% respectively; p=0.007). After propensity score-matching, the SARS-CoV-2 48 
positive group consisted of 123 patients (median 70 years of age [IQR 59-77] and 55% male) were  compared to 49 
196 patients in the matched control group (median 69 years (IQR 58 – 75] and 53% male). The 30-day mortality 50 
rate and risk were greater in the SARS-CoV-2 positive group compared to the matched control group (12% 51 
versus 4%, p=0.009 and OR 3.4 [95%CI 1.5 – 8.5], p=0.005, respectively) . Overall, pulmonary and 52 
thromboembolic complications occurred more often in SARS-CoV-2 positive patients (p<0.01).  53 
 54 
Conclusions  55 
Patients diagnosed with perioperative SARS-CoV-2 have n increased risk of 30-day mortality, pulmonary 56 
complications, and thromboembolic events. These findings  serve as an evidence-based argument to postpone 57 










Introduction  59 
 60 
The worldwide pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over61 
nine million registered coronavirus disease 2019 (COVID-19) cases and led to major disruptions of the global 62 
health care system.1 During the current peak of the pandemic, surgical theatres and recovery areas have been 63 
converted to intensive care unit (ICU) facilities to reat patients with SARS-CoV-2 infections.2 As a 64 
consequence, the global capacity for elective surgical care has decreased markedly with an estimated number of 65 
2.4 million cases per week.3 Nevertheless, surgical emergency and urgent elective procedures needed to be 66 
continued in endemic areas. A recently published study of 1128 patients with perioperative SARS-CoV-2 67 
infections of patients undergoing an operation in various health care systems across the world reported a 30-day 68 
postoperative overall mortality rate of 24%.4 Pulmonary complications were reported in 51% of patients. The 69 
24% mortality rate in SARS-CoV-2 positive patients is unusually high compared to routine reported rates in 70 
similar elective and emergency operations prior to the pandemic.5,6 Recently,  a retrospective, case-control study 71 
from Italy reported a 20% 30-day postoperative overall-mortality rate (OR 9.5, 95% CI 1.8 - 96.5) and a greater 72 
risk of pulmonary complications (OR 35.6, 95% CI 9.3 - 205.6) and thromboembolic complications (OR 13.2, 73 
95% CI 1.5 – ∞) in 41 SARS-CoV-2 positive patients compared to a mainly historic control cohort.7 Although of 74 
relevance, this single-center study has limitations due to the small sample of SARS-CoV-2 positive patients and 75 
the overall design resulting in inaccurate estimates. It is therefore, important to provide clinicians with more 76 
accurate data to improve perioperative clinical decision-making for this patient category during the foreseen new 77 
waves of SARS-CoV-2 infections. This current multicenter, nationwide, matched-cohort study compares th 30-78 
day postoperative morbidity and mortality rates between SARS-CoV-2 positive and negative patients undergoing 79 
elective or emergency operations in hospitals within a similar health care system and standardized surgical 80 
guidelines. Results of this study will provide a more reliable insight into the actual difference in overall mortality 81 










Methods  83 
 84 
Setting 85 
This nationwide, multicenter, observational, cross-sectional retro- and prospective cohort study was conducted in 86 
the Kingdom of the Netherlands. The study protocol was designed at the University Medical Center Groningen 87 
(UMCG) and approved after an expedited review by the respective local ethical review committees of 88 
participating centers (METc 2020/170, non-WMO approval). Data-transfer agreements between UMCG and 89 
participating centers were established. Informed consent of included patients was acquired in-line with local 90 
regulations. Dutch surgeons were informed about this study with regular updates via the Dutch Surgical Society. 91 
From the first week of April, nationwide, routine, preoperative screening by quantitative reverse transcription 92 
polymerase chain reaction (PCR) with or without a computed tomography (CT) of the chest was implemented 93 
per standard of care.8 The SARS-CoV-2 positive cohort was established from consecutive patients with a pre- or 94 
postoperative SARS-CoV-2 positive status who underwent an operation between February 27th and June 1st 2020 95 
in 27 centers across the Kingdom of the Netherlands, covering 10 out of 12 provinces. The negative control 96 
group was recruited at four of the 27 centers (Hospital Bernhoven [Uden], Medical Center Leeuwarden 97 
[Leeuwarden], Radboud University Medical Center [Nijmegen] and University Medical Center Groningen 98 
[Groningen]) consisting of consecutive SARS-CoV-2 negative patients who underwent routine preoperative 99 
SARS-CoV-2 PCR screening. These four centers (two teaching hospitals and two tertiary referral centers) were 100 
chosen intentionally and spread across the country to include geographic areas with different incidence rates of 101 
SARS-CoV-2. When no 30-day follow-up was planned, patients were contacted per phone by coordinating 102 
researchers to acquire final follow-up status.  103 
 104 
Inclusion and exclusion criteria 105 
Patients eligible for inclusion in the SARS-CoV-2 positive cohort either had a SARS-CoV-2 positive PCR test 106 
(nasopharyngeal or throat swab) or a strong clinical suspicion combined with a computed tomography (CT) of 107 
the chest defined as suspect for SARS-CoV-2 infection 30 days prior to surgery or within 30 days 108 
postoperatively. Patients eligible for inclusion in the control group had a negative SARS-CoV-2 history, tested 109 
negative for SARS-CoV-2 during preoperative screening with PCR and remained negative during the 30-days of 110 
follow-up. The SARS-CoV-2 status during follow-up was assessed clinically based on symptomatology, without 111 










included in both cohorts on the condition of availability of completed 30-day follow-up. Patients were excluded 113 
when data were insufficient or follow-up information could not be completed. 114 
 115 
Data acquisition and management 116 
Data were collected and managed using the REDCap electronic data capture tool (version 8.10.18, Vanderbilt 117 
University, Nashville, United States).9 Pseudo anonymized data was entered manually from the electronic patient 118 
file in the electronic case report form by local researchers of the respective participating centers and cross-119 
checked for inconsistencies and missing data by the coordinating researchers prior to data locking. Per sit , a de-120 
identification key was stored in an on-site, secured, digital data storage area. Center-specific data were accessible 121 
by local researchers and the coordinating researchers from the UMCG (SK, PKCJ, WYvdP, PJS, JPPMdV). 122 
Prior to analysis, parameters were checked for completion per case, and data were curated by coordinating 123 
researchers.  124 
 125 
Study parameters  126 
Baseline patient demographics, comorbidity status, and drug use at initial presentation were recorded. The 127 
prevalence of SARS-CoV-2 positive people per 1000 habitants per municipality on the 1st of May was acquired 128 
from the Dutch government.10 Clinical symptoms at SARS-CoV-2 diagnosis were scored. The Charlson 129 
Comorbidity Index (CCI) was calculated.11 Operative  procedures were graded with the surgical risk 130 
stratification from the University of California Los Angeles, a numerical value to reflect the risk leve  associated 131 
with the operation ranging from 1 (very low risk) to 5 (very high risk).12 Overall survival, SARS-CoV-2 132 
infection status, and complication rates (according to the Clavien-Dindo classification and summarized by the 133 
Comprehensive Complication Index) were scored at 30 days from the index operation.13,14 Pulmonary 134 
complications were diagnosed either clinically (ie respiratory insufficiency) or with imaging (ie pneumonia, 135 
ARDS). Clinically diagnosed thromboembolic complicat ons were confirmed with imaging.  136 
 137 
Study end points  138 
The primary endpoint was defined as the overall, 30-day postoperative mortality rate. As secondary outc mes, 139 
complication rate, complication severity, pulmonary complications, and thromboembolic events were compared 140 











Statistical analyses 143 
Bivariate frequencies were calculated for the descriptive analysis. Missing data were included in the descriptive 144 
analyses. The χ2 test was used for categorical data, and logistic modeling was used for calculating odds ratios 145 
with 95% confidence intervals (CIs). Propensity score-matching was used to help control for differences at 146 
baseline between those patients undergoing an operation who had a preoperative SARS-CoV-2 infection or who 147 
developed a SARS-CoV-2 infection within the immediate 30 days postoperatively and  those patients 148 
undergoing an operation without SARS-CoV-2 infection confirmed pre- or postoperatively. Cohorts were 149 
matched by age, sex, body-mass index (BMI), smoking status, preoperative comorbidities (diabetes, 150 
hypertension, congestive heart failure, myocardial inf rction, peripheral vascular disease, cerebrovascul r events, 151 
chronical renal disease, cancer, transplant), immunos ppressive medication, ECOG (Eastern Cooperative 152 
Oncology Group)  score, Charlson comorbidity index, ASA classification, type of anesthesia, and surgical risk 153 
score. The individual propensities for infection with SARS-CoV-2 were estimated with the use of a multivariable 154 
logistic regression model that included all baseline covariates. In the propensitys core-matching analysis, the 155 
nearest-neighbor method was applied with a caliper of .25 to create a matched control sample. Various matching 156 
strategies were explored. These strategies included matching with or without replacement of patients, with or 157 
without re-estimation of the propensity scores during matching, and matching smallest or largest distance first. 158 
Assessment of the covariate balance was done by comparing standardized differences before and after matching. 159 
The analysis of the primary and secondary outcomes wa done by using the matched sample. Multiple 160 
imputation was used to handle missing data, and model estimates and standard errors were calculated with 161 
Rubin’s rules.15 Finally, a subgroup analysis was performed including only patients with a SARS-CoV-2 positive 162 
status diagnosed either seven days pre- or postoperatively. Statistical analysis was performed using R version 163 
4.0.0 (R Foundation for Statistical Computing). Imputation was done using the MICE-package and matching was 164 










Results  166 
 167 
Description of the cohort 168 
A total of 558 patients undergoing an operation during the pandemic were screened for study inclusion. 169 
Ultimately, 161 SARS-CoV-2 positive and 342 SARS-CoV-2 negative controls with complete 30-day 170 
postoperative follow-up were included in the unmatched cohort (Figure 1). Baseline characteristics of the171 
included patients are shown in Table 1. The 342 SAR-CoV-2 negative patients underwent operative 172 
intervention in Hospital Bernhoven (23 [7%]), Medical Center Leeuwarden (124 [36%]), University Medical 173 
Center Groningen (93 [27%]) and at the Radboud Univers ty Medical Center (102 [30%]). After propensity-174 
matching, a matched cohort of 123 SARS-CoV-2 positive and 196 SARS-CoV-2 negative controls was 175 
established (Table 1). The distribution of the estima ed propensity scores for a positive SARS-CoV-2 statu  176 
among SARS-CoV-2 positive and negative controls is shown in Supplemental Figure 1. Odds ratios for a 177 
positive SARS-CoV-2 status according to all the variables included in the propensity score model are shown in 178 
Supplemental Table 1. The C-statistic for the model was 0.78. The differences between SARS-CoV-2 statu nd 179 
baseline variables were attenuated in the propensity score-matched samples as compared with the unmatched 180 
samples (Supplemental Figure 2). An overview of operative  procedures in the unmatched and matched cohorts 181 
is provided in Supplemental Table 2.  182 
 183 
SARS-CoV-2 positive patients 184 
The 161 patients with perioperative SARS-CoV-2 positive status underwent operations in 27 centers. 185 
Distribution of participating centers across the Netherlands combined with the prevalence of confirmed SARS-186 
CoV-2 positive people per municipality in May 2020 is presented in Figure 2. The majority of SARS-CoV-2 187 
positive patients was male (89 [55%]) with a median age of 72 years (IQR 62 – 78). Patients with a perio ative 188 
SARS-CoV-2 infection underwent mainly elective operations (87 [54%]) with general anesthesia (118 [73%]), 189 
as shown in Table 1; the majority of patients (92 [57%]) was diagnosed postoperatively with SARS-CoV-2. In 190 
case of preoperative diagnosis, median time from SAR -CoV-2 diagnosis to operation was 8 days (IQR 2 – 22 191 
days). For the 92 patients diagnosed postoperatively, median time from the operation  to diagnosis was8 days 192 
(IQR 3 – 17 days). The diagnosis SARS-CoV-2 was made with positive PCR (150 [93%]) or a chest CT highly 193 
suspicious for SARS-CoV-2 in combination with clinical symptoms (11 [7%]). Eleven patients (7%) had an 194 










positive patients (n=140) presented with 1 or more symptoms. The five most prevalent symptoms at diagnosis 196 
were fever (94 [58%]), cough (84 [52%]), tiredness (74 [46%]), dyspnea (66 [41%]) and abdominal pain (26197 
[23%]). SARS-CoV-2 positive patients received treatment on the ward (101 [63%]), in the ICU (40 [25%]), at 198 
home quarantine, a nursing home, a rehabilitation ce ter (17 [11%]) or at an unknown location (3 [2%]). 199 
Endotracheal ventilation as treatment for SARS-CoV-2 was required in 33 patients (21%) and no extracorporeal 200 
membrane oxygenation was performed. According to the primary outcome (survivor vs. non-survivor), more 201 
details of the unmatched SARS-CoV-2 group are listed in Table 2. Of the non-survivor group (n=26), patients 202 
were generally older. Deceased patients had diabetes, hypertension or peripheral vascular disease more 203 
frequently. Additionally, they had a worse ECOG performance status and higher ASA classification. No 204 
difference was found in the proportion of patients who underwent emergency operations or elective operations 205 
among the two groups (45% emergency surgery in the SARS-CoV-2 positive survivors versus 46% emergency 206 
surgery in the SARS-CoV-2 non-survivors, p=0.99). Finally, there was no difference in the proportion of 207 
symptomatic patients in the non-survivor group compared to the patients who were alive at 30-days follow-up.  208 
 209 
Primary outcome 210 
Before propensity matching, the 30-day overall postoperative mortality rate in SARS-CoV-2 positive and 211 
negative patients was 16% and 4%, respectively (p=0.007; Table 3). In the propensity score-matched cohort, 30-212 
day overall-mortality was associated with an OR of 3.4 (95% confidence interval 1.5 – 8.5) for patients with a 213 
perioperative SARS-CoV-2 positive status compared to negative controls. The overall 30-day postoperative 214 
mortality rates for both matched and unmatched cohorts are provided in Table 3. In the subgroup of patients with 215 
a SARS-CoV-2 positive status diagnosed either seven days pre- or postoperatively, an increase in mortality rate 216 
compared to SARS-CoV-2 negative patients was confirmed (n=8 [12%] vs. n=14 (4%); p=0.009).  217 
 218 
Secondary outcomes 219 
Patients with perioperative SARS-CoV-2 had more complications (1 [IQR 0-3] vs 0 [IQR 0-1]; p<0.001) with a 220 
higher comprehensive complication index (21 [IQR 0 – 40]) vs 0 [IQR 0 – 12], p<0.001) compared to matched 221 
negative controls. The number of grade II and grade IV complications was greater in the matched SARS-CoV-2 222 
positive cohort (p<0.01). Pulmonary complications occurred in 25 (20%) SARS-CoV-2 positive patients and in 6 223 
(3%) matched SARS-CoV-2 negative patients (p<0.001). Similarly, the number of patients with thromboembolic 224 










[0.5%], p=0.004). There was no difference in hemorrhagic or infectious complications between matched cohorts. 226 
An overview of the complications for matched and unmatched cohorts is provided in Table 3. Supplemental 227 
Table 3 gives a detailed description of the diagnosed pulmonary complications and thromboembolic events. 228 










Discussion  230 
 231 
This nationwide, cohort study compares morbidity and mortality rates between matched patients with and232 
without SARS-CoV-2 infection undergoing emergency or elective operations during the first wave of the 233 
pandemic. We found that s pre- or postoperative positive SARS-CoV-2 status was associated with a greate  30-234 
day postoperative, overall mortality rate and a 3.4-fold (95% confidence interval 1.5 – 8.5) increased overall 235 
mortality risk compared to matched control patients with a negative SARS-CoV-2 status. SARS-CoV-2 positive 236 
patients develop a greater number and more serious p stoperative complications. Pulmonary complications a d 237 
thromboembolic events are more prevalent in patients wi h perioperative SARS-CoV-2.  Although several 238 
previous studies  suggested this increase in mortality and morbidity, this is the first study to use a well-matched 239 
control group to provide good, evidence-based support for this clinical observation.  240 
 241 
In this study, 30-day overall mortality rate in the unmatched SARS-CoV-2 positive cohort was 16% compared to 242 
4% in the surgical control group. SARS-CoV-2 positive patients included in our study had a median age of 72 243 
years. The worldwide COVID-19 overall case fatality rate for SARS-CoV-2 positive patients of the same ag244 
category 8%.18 The increased mortality rate of SARS-CoV-2 positive patients in this age category who 245 
underwent surgery might be attributed to a synergistic effect of SARS-CoV-2 and surgery. The 30-day mortality 246 
rate of surgical patients with a perioperative SARS-CoV-2 infection in our study is less than the previously 247 
reported 20.5 – 23.8% mortality rates.4,19,20 The difference may be attributed to the fact that we included patients 248 
treated in a health care system with negligible quality differences between hospitals with similar circumstances, 249 
and time frame.  250 
The underlying pathophysiologic mechanisms of the increased mortality rate of SARS-CoV-2 positive patients 251 
undergoing surgery is still unknown. Mechanical ventilation, anesthesia itself, or tissue damage caused by the 252 
operation may each provoke a pro-inflammatory cytokine and immunosuppressive response, potentially 253 
worsening the presentation of a pre- or postoperative SARS-CoV-infection.19,21. Surgery-related thromboembolic 254 
and pulmonary complications in addition to the  underlying effects of the SARS-CoV-2 infection may further 255 
increase the risk of thrombotic effects in the pulmonary circulation, respiratory insufficiency, respiratory distress 256 
syndrome (ARDS) and eventually death.20,22 We found a mortality rate of 4% in the SARS-CoV-2 negative 257 
control group,  which is twice as high compared to the rate of 2% reported in a Dutch national registry that 258 










caused by the inclusion of patients undergoing emergency surgery or the selection of patients with more urgent 260 
indications to undergo elective operations during the pandemic. The rate of pulmonary complications in SARS-261 
CoV-2 positive patients included in our study (24%) is less than previous studies (41% - 51%) in patients with 262 
perioperative SARS-CoV-2. The  reason for this lesser rate is unclear but might be attributed to either under- or 263 
over reporting or different characteristics of included patients. It is likely that pulmonary complicat ons are a 264 
direct consequence of SARS-CoV-2, potentially increased in severity by an operation or anesthesia.4,7 Little is 265 
known about increased postoperative thromboembolic events in SARS-CoV-2. It is suggested that that the 266 
coagulopathy associated with COVID-19 might be attribu ed to a combination of disseminated intravascular 267 
coagulation and localized pulmonary thrombotic microangiopathy.23  Thromboembolic events have been 268 
described previously as a major risk factor for mortality in hospitalized patients with SARS-CoV2.24,25  Future 269 
studies with larger cohorts of surgical patients are needed to further confirm our observations and assess the 270 
association between thromboembolic events and postoerative mortality. 271 
Comparing outcomes of surgery between hospitals within a uniform health care system allows for accurate 272 
assessment of differences in morbidity and mortality between SARS-CoV-2 positive and negative patients. We 273 
used propensity-score-matching in an attempt to accunt for a wide variety of baseline differences. Our study 274 
still, however, has limitations we need to address. Despite the propensity matching, it is still possible that some 275 
amount of unmeasured confounding remains. The SARS-CoV-2 positive cohort is a heterogeneous group, 276 
consisting of asymptomatic and symptomatic patients diagnosed pre- or postoperatively. Especially at the277 
beginning of the first wave of SARS-CoV-2 infections in the Netherlands, testing capacity was limited, and 278 
patients could not be screened routinely prior to their operation. This reality is reflected by the proportion of 279 
patients with a postoperative SARS-CoV-2 status within the 30 days postoperatively. It is likely that many, 280 
perhaps most of the patients with a positive postoperative SARS-CoV-2 status were already infected during the 281 
index operation; however,  the exact number of patients with a preoperative SARS-CoV-2 status  is unknown, 282 
because a proportion of preoperative SARS-CoV-2 infections was diagnosed postoperatively. Additionally, the 283 
median SARS-CoV-2 incubation period from time to symptom onset is 5 days, which may further bias the 284 
differentiation between preoperative, postoperative, in-hospital and out-of hospital infections.26,27 Unfortunately, 285 
we cannot dissect out  these possibilities. Routine preoperative testing was implemented nationally as st ndard of 286 
care from April onward.8 Furthermore, because screening for SARS-CoV-2 was also not performed routinely 287 
after surgery, it is likely that patients with an uexpected adverse postoperative course were more prne to be 288 










potentially leading to an overreported mortality and morbidity rate. Additionally, the elective surgery capacity in 290 
the Netherlands during the initial wave of SARS-CoV-2 was severely impaired. Semi- urgent operations, 291 
however, were still performed without evidence of the potential risk of a SARS-CoV-2 infection in combination 292 
with surgery.Therefore , patients who underwent surgical interventions in this timeframe are not representative 293 
of the general population undergoing elective surgery prior to the pandemic. Probably, based on the limited 294 
elective capacity in the hospitals, ,surgeons prioritized more urgent elective procedures such as for instance semi 295 
acute cancer- and trauma surgery. 296 
The findings of this study have direct implications for the perioperative delivery of health care, because  medical 297 
professionals across the world will be confronted continuously with SARS-CoV-2 until effective vaccination 298 
programs have been established or herd immunity is reached. The high morbidity and mortality risk among 299 
perioperative SARS-CoV2 positive patients should be an argument to postpone elective operations and even300 
reconsider emergency operative interventions in select d patients, especially those at risk for pulmonary or 301 
thromboembolic complications. Surgeons on call will have to cope with acute dilemmas and at least consider 302 
alternative strategies to operative intervention. Surgical strategies in SARS-CoV-2 positive patients i  need of 303 
emergency surgery may be changed toward a conservativ  approach; for instance, antibiotics for appendicitis or 304 
acute cholecystitis may be chosen instead of operativ  therapy. Results of our study further underline th  305 
relevance of pre-operative testing of all patients i  areas that have a high risk of SARS-CoV-2 infection. Current 306 
Dutch consensus documents advise to double the dosage of thromboembolic prophylaxis of SARS-CoV-2 307 
positive patients during ICU admission with respect to the risk of bleeding.28 The high rate of postoperative 308 
thromboembolic events in SARS-CoV-2 positive patients undergoing operations might address the need for 309 
personalized protocols of thromboembolic prophylaxis in this patient category. Models of surgical risk 310 
stratification tailored to individual SARS-CoV-2 patients are needed. Previously established risk stratification 311 
systems, such as the Charlson comorbidity index, the ASA score,  or performance scores might be useful tools to 312 
estimate potential postoperative mortality in SARS-CoV-2 positive patients diagnosed pre-operatively.  313 
Therefore, it remains highly relevant to collaborate globally and to share and analyze outcomes of surgery in the 314 
SARS-CoV-2 positive population in future studies.4  315 
 316 
In conclusion, this nationwide, matched cohort study shows that a pre- or postoperative SARS-CoV-2 positive 317 
status increases 30-day overall postoperative mortality r tes, pulmonary complications. and thromboembolic 318 










operations in patients with preoperatively diagnosed SARS-CoV-2 should be postponed whenever possible and 320 
even emergency operative intervention for selected patients should be carefully reconsidered. Altered protocols 321 
of thromboembolic prophylaxis might be required to prevent thromboembolic complications  in surgical ptients 322 
with SARS-CoV-2, but the use of greater than the normal dosage of thromboembolic prophylaxis should be 323 
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Figure 1: Study flowchart 
 
Figure 2: Distribution of participating centers across the Netherlands and the prevalence of confirmed SARS-
CoV-2 positive people per 1000 habitants per municipality 
Supplemental Figure 1: Distribution of the estimated propensity score for a positive SARS-CoV-2 status mong 
SARS-CoV-2 positive and SARS-CoV-2 negative patients. On the left, histograms of propensity scores for the 
unadjusted samples who were SARS-CoV-2 positive and who were SARS-CoV-2 negative. On the right, 
histograms of the propensity matched samples. Generated using the first imputed dataset. The other imputed 
datasets are similar and available on request.  












Supplemental File 1 
 
Dutch surgical COVID-19 research collaborative – Alphabetical order of Medical Center 
 
First Name Middle Name(s) Last Name Affiliation Email Address ORCID-ID 
Djamilla  Boerma Department of Surgery, 
Antonius Ziekenhuis, 
Nieuwegein, The Netherlands 
d.boerma@antoniusziekenhuis.nl  
0000-0001-9212-1317 
Sarah L Gerritsen Department of Surgery, 
Antonius Ziekenhuis, 
Nieuwegein, The Netherlands 
sl.gerritsen@antoniusziekenhuis.nl  
Wout  van der Meij Department of Surgery, 




André S van Petersen Department of Surgery, 
Bernhoven, Uden, the 
Netherlands 
a.vanpetersen@bernhoven.nl 0000-0003-0557-8939 
Charles T Stevens Department of Surgery, 
Bernhoven, Uden, the 
Netherlands 
c.stevens@bernhoven.nl 0000-0002-4431-1287 
Marc  van Sambeek Department of Surgery, 
Catharina Ziekenhuis, 
Eindhoven, the Netherlands 
marc.v.sambeek@catharinaziekenhuis.nl  
0000-0003-4713-9045 
Marleen  Hölscher Department of Surgery, 
Catharina Ziekenhuis, 
Eindhoven, the Netherlands 
marleen.holscher@catharinaziekenhuis.nl 0000-0001-5991-3638 
Apollo  Pronk Department of Surgery, 













Wouter J Bakker Department of Surgery, 




Patrick WHE Vriens Department of Surgery, 
Elisabeth Tweesteden 




Thymen  Houwen Department of Surgery, 
Elisabeth Tweesteden 
Ziekenhuis, Tilburg, the 
Netherlands 
t.houwen@etz.nl 0000-0002-2441-3892 




Tammo S de Vries Reilingh Elkerliek, Helmond, the 
Netherlands 
chirurgen@elkerliek.nl 0000-0001-8456-701X 
Ellis  Schipper Elkerliek, Helmond, the 
Netherlands 
eschipper@elkerliek.nl 0000-0002-5217-5588 
Pascal HE Teeuwen Elkerliek, Helmond, the 
Netherlands 
chirurgen@elkerliek.nl  
Tessa M van Ginhoven Department of Surgery, 
Erasmus Universitair 
Medisch Centrum, 
Rotterdam, the Netherlands 
t.vanginhoven@erasmusmc.nl  
0000-0002-9365-4892 
Charlotte  Viëtor Department of Surgery, 
Erasmus Universitair 
Medisch Centrum, 
Rotterdam, the Netherlands 
380118cv@student.eur.nl 0000-0002-0177-2606 
Mark JW van der Oest Department of Plastic, 
Reconstructive and Hand 
Surgery, Erasmus Medical 
Center, Rotterdam, The 
Netherlands 
 
Department of Rehabilitation 
Medicine, Erasmus Medical 
Center, Rotterdam, The 
Netherlands 
 
Hand and Wrist Center, Xpert 












Sarah  Gans Department of Surgery, Gelre 




Peter  van Duijvendijk Department of Surgery, Gelre 
Ziekenhuis, Apeldoorn, the 
Netherlands 
p.van.duijvendijk@gelre.nl 0000-0002-0441-6180 
Tanneke  Herklots Department of Surgery, Gelre 
Ziekenhuis, Apeldoorn, the 
Netherlands 
t.herklots@gelre.nl 0000-0003-4513-0063 
Tom  de Hoop Department of Surgery, Gelre 




Michelle  de Graaff Department of Surgery, Gelre 
Ziekenhuis, Apeldoorn, the 
Netherlands 
m.de.graaff@gelre.nl  
Didi  Sloothaak Department of Surgery, Gelre 
Ziekenhuis, Apeldoorn, the 
Netherlands 
d.sloothaak@gelre.nl 0000-0002-5957-5824 
Marieke  Bolster - van Eenennaam Department of Surgery, Gelre 




Jedidja  Baaij Department of Surgery, Gelre 
Ziekenhuis, Apeldoorn, the 
Netherlands 
j.baaij@gelre.nl 0000-0001-9962-8583 
Maarten  Vermaas Department of Surgery, 
IJsselland Ziekenhuis, 




Kelly R Voigt Department of Surgery, 
IJsselland Ziekenhuis, 
Capelle aan den IJssel, the 
Netherlands 
kvoigt@ysl.nl 0000-0002-5149-9476 
Gijs A Patijn Department of Surgery, Isala 




Amarins TA Bransma Department of Surgery, Isala 













Wouter KG Leclercq Department of Surgery, 
Maxima Medisch Centrum, 









Department of Surgery, 
 
Maxima Medisch Centrum, 
Veldhoven, the Netherlands 
julie.sijmons@mmc.nl 0000-0002-4914-4537 
Martine  Uittenbogaart Department of Surgery, 
 
Maxima Medisch Centrum, 
Veldhoven, the Netherlands 
M.Uittenbogaart@mmc.nl 0000-0001-8099-8322 
Paul M Verheijen Department of Surgery, 
 
Meander Medisch Centrum, 
Amersfoort & Baarn, the 
Netherlands 
pm.verheijen@meandermc.nl  
Thijs A Burghgraef Department of Surgery, 
 
Meander Medisch Centrum, 
Amersfoort & Baarn, the 
Netherlands 
TA.Burghgraef@meandermc.nl 0000-0001-8781-9630 
Marloes  Emous Department of Surgery, 
Medical Center Leeuwarden, 
Leeuwarden, the Netherlands 
marloes.emous@mcl.nl  
0000-0002-2223-3687 
Ralph  Poelstra Department of Surgery, 
Medical Center Leeuwarden, 
Leeuwarden, the Netherlands 
ralph.poelstra@mcl.nl 0000-0003-3592-1136 
Manon  Teunissen Department of Surgery, 
Medical Center Leeuwarden, 
Leeuwarden, the Netherlands 
m.teunissen.3@student.rug.nl  












   Noordwest Ziekenhuisgroep, 
Alkmaar & Den Helder, the 
Netherlands 
  
Said  Bachiri Department of Surgery, 
 
Noordwest Ziekenhuisgroep, 
Alkmaar & Den Helder, the 
Netherlands 
s.bachiri@nwz.nl 0000-0001-5246-3494 
Lennaert CB Groen Department of Surgery, 
 
Noordwest Ziekenhuisgroep, 
Alkmaar & Den Helder, the 
Netherlands 
lcb.groen@nwz.nl 0000-0002-0530-7162 
Philip R de Reuver Department of Surgery, 
Radboud University Medical 




Floris M Thunissen Department of Surgery, 
Radboud University Medical 
Center, Nijmegen, the 
Netherlands 
floris.thunnissen@radboudumc.nl  
Britt AM Vermeulen Department of Surgery, 
Radboud University Medical 
Center, Nijmegen, the 
Netherlands 
ba.vermeulen@student.ru.nl 0000-0002-1012-7991 
Anna  Groen Department of Surgery, 
Radboud University Medical 
Center, Nijmegen, the 
Netherlands 
A1.Groen@student.ru.nl 0000-0001-6177-9407 
Ramon RJP van Eekeren Department of Surgery, 
Rijnstate, Arnhem, the 
Netherlands 
rvaneekeren@rijnstate.nl 0000-0003-0509-1346 
Ernst J Spillenaar Bilgen Department of Surgery, 













Niels J Harlaar Department of Surgery, Rode 
Kruis Ziekenhuis, Beverwijk, 
the Netherlands 
 
Department of Surgery, 
 
Noordwest Ziekenhuisgroep, 




Fredrik HW Jonker Department of Surgery, Rode 
Kruis Ziekenhuis, Beverwijk, 
the Netherlands 
 
Department of Surgery, 
 
Noordwest Ziekenhuisgroep, 
Alkmaar & Den Helder, the 
Netherlands 
fjonker@rkz.nl 0000-0001-8433-7388 
Sjirk W van der Burg Department of Surgery, Rode 
Kruis Ziekenhuis, Beverwijk, 
the Netherlands 
svanderburg@rkz.nl 0000-0002-9243-242X 
Lisanne AE Posma-Bouman Department of Surgery, 
Slingeland, Doetinchem, the 
Netherlands 
L.Posma@slingeland.nl 0314 329 911 
Steven J Oosterling Department of Surgery, 
Spaarne Gasthuis, Haarlem & 
Hoofddorp, the Netherlands 
sj.oosterling@spaarnegasthuis.nl  
0000-0002-9789-2775 
Josephine  Franken Department of Surgery, 
Spaarne Gasthuis, Haarlem & 
Hoofddorp, the Netherlands 
jfranken@spaargegasthuis.nl 0000-0002-8629-0920 
David R Nellensteijn Department of Surgery, 






 Bensi Department of Surgery, 













Wim  van den Broek Department of Surgery, Sint 
Anna Ziekenhuis, Geldrop, 
the Netherlands 
w.vanden.broek@st-anna.nl 0000-0002-5149-9476 
Eduard R Hendriks Department of Surgery, 
Tergooi, Hilversum & 
Blaricum, The Netherlands 
ehendriks@tergooi.nl  
0000-0001-9770-1089 
Anna AW van Geloven Department of Surgery, 
Tergooi, Hilversum & 
Blaricum, The Netherlands 
avangeloven@tergooi.nl 0000-0001-6324-9127 
Schelto  Kruijff Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
s.kruijff@umcg.nl  
Jean-Paul P.M. de Vries Department of Surgery, 
University of Groningen, 
University Medical Center 




Pieter J Steinkamp Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
p.j.steinkamp@umcg.nl 0000-0003-4228-063X 
Pascal KC Jonker Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
p.k.c.jonker@umcg.nl 0000-0002-4652-7014 
Willemijn Y van der Plas Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
w.y.van.der.plas@umcg.nl 0000-0002-5758-2959 
Wouter FW Bierman Department of Internal 
Medicine and Infectious 













   Medical Center Groningen, 
Groningen, the Netherlands 
  
Michel MRF Struys Department of 
Anesthesiology, University of 
Groningen, University 
Medical Center Groningen, 
Groningen, the Netherlands 
m.m.r.f.struys@umcg.nl  
Yester F Janssen Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
y.f.janssen@umcg.nl 0000-0003-1271-3780 
Gooitzen M van Dam Deptartments of surgery, 
nuclear medicine and 
molecular imaging, medical 
imaging center, University of 
Groningen, University 
Medical Center Groningen, 
Groningen, the Netherlands 
go@tracercro.com  
Frank FA IJpma Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
f.f.a.ijpma@umcg.nl  
Claire  van der Riet Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
c.van.der.riet@umcg.nl  
Eline  Feitsma Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
e.a.feitsma@umcg.nl  
Kirsten  Ma Department of Surgery, 
University of Groningen, 
University Medical Center 













Simone  Kleiss Department of Surgery, 
University of Groningen, 
University Medical Center 
Groningen, Groningen, the 
Netherlands 
s.f.kleiss@umcg.nl  
Milan C Richir Department of Surgery, 
University Medical Center 
Utrecht, Utrecht, the 
Netherlands 
mrichir@umcutrecht.nl  
Menno R Vriens Department of Surgery, 
University Medical Center 
Utrecht, Utrecht, the 
Netherlands 
mvriens@umcutrecht.nl  
Mando D Filipe Department of Surgery, 
University Medical Center 
Utrecht, Utrecht, the 
Netherlands 
M.D.Filipe-2@umcutrecht.nl 0000-0002-9869-7840 
Frank C den Boer Department of Surgery, Zaans 




Nicole AM Dekker Department of Surgery, Zaans 
Medisch Centrum, Zaandam, 
the Netherlands 
Dekker.N@zaansmc.nl 0000-0002-0300-3026 
Tim  Verhagen Department of Surgery, 
Ziekenhuis Groep Twente, 




Floor  ter Brugge Department of Surgery, 
Ziekenhuis Groep Twente, 
Almelo & Hengelo, the 
Netherlands 
f.tbrugge@zgt.nl 0000-0002-7208-2354 
Emmanuel AGL Lagae Department of Surgery, 
Zorgsaam Zeeuws 














Evert-Jan G Boerma Zuyderland Medisch 




Donald  Schweitzer Zuyderland Medisch 
Centrum, Sittard & Geleen, 
the Netherlands 
d.schweitzer@zuyderland.nl 0000-0003-4038-0952 
Mark HF Keulen Zuyderland Medisch 
Centrum, Sittard & Geleen, 
the Netherlands 
mar.keulen@zuyderland.nl 0000-0003-0029-3598 
Shirley  Ketting Zuyderland Medisch 













Table 1 – Baseline characteristics of the unmatched and propensity-score matched patient groups 
 Unmatched patients Propensity-score matched patients* 
 SARS-CoV-2 
positive patients 
N = 161 
SARS-CoV-2 
negative patients 
N = 342 
SARS-CoV-2 
positive patients 
N = 123 
SARS-CoV-2 
negative patients 
N = 196 
Age category – no (%)     
< 50y 14 (8.7) 89 (26.0) 13 (10.6) 19 (9.7) 
50 - < 70y 51 (31.7) 138 (40.4) 47 (38.2) 80 (40.8) 
≥ 70y 95 (59.0) 115 (33.6) 63 (51.2) 97 (49.5) 
Female sex – no (%) 72 (44.7) 161 (47.1) 56 (45.5) 93 (47.4) 
BMI – no (%)     
 < 18,5 7 (4.3) 29 (8.5) 6 (4.9) 10 (5.1) 
18,5 - < 25 49 (30.4) 117 (34.2) 41 (33.3) 65 (33.2) 
25 - < 30 46 (28.6) 112 (32.7) 39 (31.7) 66 (33.7) 
30 - < 35 32 (19.6) 49 (14.3) 24 (19.5) 38 (19.4) 
35 - < 40 12 (7.5) 21 (6.1) 10 (8.1) 15 (7.7) 
≥ 40 5 (3.1) 3 (0.9) 3 (2.4) 2 (1.0) 
Missing  10 (6.2) 11 (3.2) 0 0 
Current smoker – no (%) 18 (11.2) 47 (13.7) 21 (17.1) 33 (16.8) 
Missing 33 (20.5) 71 (20.8) 0 0 
Diabetes – no (%) 44 (27.3) 42 (12.3) 22 (18) 35 (18)
Hypertension – no (%) 80 (49.7) 105 (30.7) 53 (43.1) 87 (44.4) 
Missing 0 (0.0) 13 (3.8) 0 0 
Congestive heart failure – no (%) 13 (8.1) 19 (5.6) 8 (6.5) 13 (6.6) 
Myocardial infarct – no (%) 21 (13.0) 24 (7.0) 12 (9.8) 19 (9.7) 
Peripheral vascular disease – no (%) 26 (16.1) 40 (11.7) 16 (13) 27 (14) 
Chronic pulmonary disease – no (%) 20 (12..4) 26 (7. ) 10 (8.1) 20 (10) 
CVA – no (%) 24 (14.9) 31 (9.1) 13 (11) 21 (11) 
Chronic renal disease – no (%) 22 (13.7) 25 (7.3) 10 (8.1) 16 (8.2) 
Cancer – no (%) 30 (18.6) 123 (36.0) 27 (22) 47 (24)
Transplant – no (%) 1 (0.6) 7 (2.0) 1 (0.8) 1 (0.5) 
Missing 2 (1.2) 2 (0.6) 0 0 
Immunosuppression – no (%) 10 (6.2) 17 (5.0) 9 (7.3) 10 (5.1) 
Missing 0 6 (1.8) 0 0 
ECOG score     
0 - 1 93 (57.8) 288 (84.2) 92 (75) 155 (79) 
2 26 (16.1) 29 (8.5) 21 (17) 25 (13) 
3 – 4  30 (18.6) 18 (5.3) 10 (8.1) 16 (8.2) 
Missing 12 (7.5) 7 (2.0) 0 0 
Charlson Comorbidity Index – median (IQR) 4 (2-7) 4 (2-6) 4 (2-6) 4 (2-6) 
Missing 0 (0.0) 1 (0.3) 0 0 
ASA classification – no (%)     
I – II 60 (37.3) 169 (49.4) 54 (44) 87 (44) 
III – IV 97 (60.2) 170 (49.7) 69 (56) 109 (56) 
Missing 4 (2.5) 3 (0.9) 0 0 
Anaesthesia – no (%)     
General 118 (73.3) 291 98 (80) 156 (80) 
Other (including spinal) 43 (26.7) 51 25 (20) 40 (20) 
Missing 0 (0.0) 0 (0.0) 0 0 
Type of Operation – no (%)     
Elective 87 (54.0) 252 (73.7) 76 (62) 131 (67) 
Emergency 73 (45.3) 84 (24.6) 47 (38) 65 (33) 
Missing 1 (0.6) 6 (1.8) 0 0 
Surgical risk score – no (%)     
1-2 42 (26.1) 72 (21.1) 35 (29) 48 (25) 
3 64 (39.8) 135 (39.5) 47 (38) 86 (44) 
4 36 (22.4) 100 (29.2) 31 (25) 48 (25) 
5 10 (6.2) 31 (9.1) 10 (8.1) 14 (7.1) 
Missing 9 (5.6) 4 (1.2) 0 0 
BMI, body mass index; CVA, cerebrovascular accident, ECOG; Eastern Cooperative Oncology Group; IQR, interquartile range; ASA, 
American Society of Anaesthesiologists  









Table 2 – Description of SARS-CoV-2 positive survivors and non-survivors (unmatched cohort)  
 
SARS-CoV-2 positive patients 
Survivors 
N = 135 
SARS-CoV-2 positive patients 
Non-survivors 
N = 26 
p-value 
Patient characteristics 
Age category – no (%)   <0.001 
< 50y 14 (10.4) 0 (0.0)  
50 - < 70y 49 (36.6) 2 (7.7)  
≥ 70y 71 (53.0) 24 (92.3)  
Female sex – no (%) 62 (45.9) 10 (38.5) 0.63 
BMI – no (%)   0.93 
 < 18,5 5 (3.7) 2 (7.7)  
18,5 - < 25 40 (29.6) 9 (34.6)  
25 - < 30 40 (29.6) 6 (23.1)  
30 - < 35 26 (19.3) 6 (23.1)  
35 - < 40 10 (7.4) 2 (7.7)  
≥ 40 4 (3.0) 1 (3.8)  
Current smoker – no (%) 14 (10.4) 4 (15.4) 0.71 
Diabetes – no (%) 32 (23.7) 12 (46.2) 0.04 
Hypertension – no (%) 64 (47.4) 16 (61.5)  
Congestive heart failure – no (%) 7 (5.2) 6 (23.1)  
Myocardial infarct – no (%) 13 (9.6) 8 (30.3) 0.27 
Peripheral vascular disease – no (%) 16 (11.9) 10 (38.5) 0.002 
Chronic pulmonary disease – no (%) 14 (10.4) 6 (23.1) 0.14 
CVA – no (%) 18 (13.3) 6 (23.1) 0.33 
Chronic renal disease – no (%) 15 (11.1) 7 (26.9) 0.07 
Cancer – no (%) 26 (19.3) 4 (15.4) 0.85 
Transplant – no (%) 0 (0.0) 1 (3.8) 1.00 
Immunosuppression – no (%) 9 (6.7) 1 (3.8) 0.92 
ECOG score   0.002 
0 - 1 84 (62.2) 9 (34.6)  
2 22 (16.3) 4 (15.4)  
3 – 4  19 (14.1) 11 (42.3)  
Charlson Comorbidity Index – median (IQR) 4.0 (2.0 – 6.0) 6.5 (4.0 – 8.9) 0.001 
Surgery characteristics 
ASA classification – no (%)   0.02 
I – II 56 (41.5) 4 (15.4)  
III – IV 75 (55.6) 22 (84.6)  
Anaesthesia – no (%)   0.79 
General 100 (74.1) 18 (69.2)  
Other (including spinal) 35 (25.9) 8 (30.8)  
Type of Operation – no (%)   1.00 
Elective 73 (54.1) 14 (53.8)  
Emergency 61 (45.2) 12 (46.2)  
Surgical risk score – no (%)   0.06 
1-2 39 (38.9) 3 (11.5)  
3 47 (34.8) 17 (65.4)  
4 31 (23.0) 5 (19.2)  
5 9 (6.7) 1 (3.8)  
SARS-CoV-2 characteristics 
Timing of diagnosis – no (%)   0.001 
Preoperative 67 (49.6) 2 (7.7)  
Postoperative 68 (50.4) 24 (92.3)  
Symptomatology – no (%)   1.00 
Asymptomatic 9 (6.7) 2 (7.7)  
≥1 symptom 117 (86.7) 23 (88.5)  
BMI, body mass index; CVA, cerebrovascular accident, ECOG; Eastern Cooperative Oncology Group; IQR, interquartile range; ASA, 









Table 3 – 30-day outcomes 
 Unmatched patients  Propensity-scored matched patients  
 SARS-CoV-2 positive 
patients 
N = 161 
SARS-CoV-2 negative 
patients 




N = 123 
SARS-CoV-2 negative 
patients 
N = 196 
p-value 
30-day postoperative mortality 
30 days follow-up – no (%)   <0.001   <0.001 
Alive at hospital 26 (16.1) 25 (7.3)  21 (17.1) 13 (6.6)  
Alive at rehabilitation 35 (21.7) 21 (6.1)  25 (20.3) 16 (8.2)  
Alive at home 74 (46.0) 282 (82.5)  62 (50.4) 158 (80.6)  
Deceased 26 (16.2) 14 (4.1)  15 (12.2) 9 (4.6)  
30-day postoperative complications 
Number of complications per patient, median 
(IQR) 
1 (0 – 3) 0 (0 – 1) <0.0001 1 (0 – 2) 0 (0 – 1) <0.001 
Comprehensive Complication Index, median 
(IQR) 
20.9 (0 – 42.7) 0 (0  - 20.9) <0.0001 20.9 (0 – 39.5) 0 (0 – 12.2) <0.0001 
Pulmonary complications – no (%) 39 (24.2) 11 (3.2) <0.0001 25 (20.3) 6 (3.1) <0.0001 
Thromboembolic complications – no (%) 11 (6.8) 1 (0.3) <0.0001 8 (6.5) 1 (0.5) 0.004 
Hamorrhagic complications –  no (%) 22 (13.6) 28 (8.2) 0.052 16 (9.9) 20 (10.2) 0.49 
Infectious complications – no (%) 13 (8.1) 27 (7.8) 0.97 11 (8.9) 12 (6.1) 0.42 
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